Orgenesis to Present at the 2013 Gateway Conference on September 10

  Orgenesis, Inc. (OTCBB: ORGS), a development-stage company with a novel therapeutic technology dedicated to converting a patient's own liver cells into functioning insulin-producing cells as a treatment for diabetes, has been invited to present at the 2013 Gateway Conference being held on Tuesday, September 10, 2013 at the Palace Hotel in San Francisco.

Orgenesis CEO Sav DiPasquale is scheduled to present at 12:00 p.m. Pacific time, with one-on-one meetings held throughout the day. The presentation will also be webcast live and available for replay at www.gateway-conference.com, under the Presenting Companies tab.

For additional information or to schedule a one-on-one meeting visit www.gateway-conference.com and click on the Register/Login tab. You may also email your request to [e-mail] or call Justin Vaicek at [phone].

About the Gateway Conference The Gateway Conference is designed to provide a unique gateway between influential members of the investment community and a select group of compelling publicly-traded companies. Portfolio managers, research analysts and brokers from buy-side and sell-side institutions will have the opportunity to learn about more than 50 exciting growth companies across a broad range of industries, from technology, business and financial services, digital media and clean-tech to consumer products, retail/e-commerce, life sciences and natural resources. For more information, visit www.gateway-conference.com.

The invitation-only conference is hosted by Liolios Group, one of the nation's top investor relations agencies, and sponsored by leading firms that service the financial community. For more information about Liolios Group, visit www.liolios.com.

About Orgenesis Inc. Orgenesis (ORGS) is a development stage company with a novel therapeutic technology that employs a molecular and cellular approach directed at converting a patient's own liver cells into functional insulin producing cells, as a treatment for diabetes. The Company believes that converting the diabetic patient's own tissue into insulin-producing cells overcomes the problem of donor shortage and removes the risk of transplant rejection. If successful, this could mean the end of diabetes, as we now know it. For more information visit: www.orgenesis.com.

Add to Digg Bookmark with del.icio.us Add to Newsvine

Company Contact Dov Weinberg CFO 914-949-0631 Conference Contact: Justin Vaicek Liolios Group, Inc. Tel [phone] [e-mail] www.liolios.com